JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.C500363200 on September 22, 2005

J. Biol. Chem., Vol. 280, Issue 46, 38121-38124, November 18, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/46/38121    most recent
C500363200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenz, G.
Right arrow Articles by Avruch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenz, G.
Right arrow Articles by Avruch, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Glutamatergic Regulation of the p70S6 Kinase in Primary Mouse Neurons*{boxs}

Guido Lenz{ddagger}§ and Joseph Avruch{ddagger}1

From the {ddagger}Department of Molecular Biology and the Diabetes Unit and Medical Services, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114 and the §Department of Biophysics, IB, Universidade Federal do Rio Grande do Sul, 91501-970 Porto Alegre, RS, Brazil

Received for publication, August 24, 2005 , and in revised form, September 19, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Brief glutamatergic stimulation of neurons from fetal mice, cultured in vitro for 6 days, activates the mTOR-S6 kinase, ERK1/2 and Akt pathways, to an extent approaching that elicited by brain-derived neurotrophic factor. In contrast, sustained glutamatergic stimulation inhibits ERK, Akt, and S6K. Glutamatergic activation of S6K is calcium/calmodulin-dependent and is prevented by inhibitors of calcium/calmodulin-dependent protein kinase 2, phosphatidylinositol 3-OH-kinase and by rapamycin. 2-Amino-5-phosphonovaleric acid, an inhibitor of N'-methyl-D-aspartate receptors, abolishes glutamatergic activation of ERK1/2 but not the activation of mTOR-S6K; the latter is completely abolished by inhibitors of voltage-dependent calcium channels. Added singly, dopamine gives slight, and norepinephrine a more significant, activation of ERK and S6K; both catecholeamines, however, enhance glutamatergic activation of S6K but not ERK. After 12 days in culture, the response to direct glutamatergic activation is attenuated but can be uncovered by suppression of {gamma}-aminobutyric acid interneurons with bicuculline in the presence of the weak K+ channel blocker 4-aminopyridine (4-AP). This selective synaptic activation of mTOR-S6K is also resistant to APV and inhibited by Ca2+ channel blockers and higher concentrations of glutamate. Elongation factor 2 (EF2) is phosphorylated and inhibited by the eEF2 kinase (CaM kinase III); the latter is inhibited by the S6K or Rsk. Bicuculline/4-AP or KCl-induced depolarization reduces, whereas higher concentrations of glutamate increases, EF2 phosphorylation. Thus the mTOR-S6K pathway in neurons, a critical component of the late phase of LTP, is activated by glutamatergic stimulation in a calcium/calmodulin-dependent fashion through a calcium pool controlled by postsynaptic voltage-dependent calcium channels, whereas sustained stimulation of extrasynaptic glutamate receptors is inhibitory.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The storage of information for behavioral purposes requires that changes in synaptic strength be maintained for periods that greatly exceed the half-life of activation or even the lifetime of the proteins that participate in this process. Several positive feedback mechanisms have been proposed to account for this long lasting effect, involving mainly kinases, phosphatases, and the protein synthesis machinery (1, 2).

Protein synthesis in dendrites has emerged as an important process for the induction of the late phase of long term potentiation (LTP)2 inasmuch as it provides a mechanism by which a single synapse can undergo rapid and specific changes in protein composition, and therefore in physiological activity, without significantly affecting most other synapses in the same neuron. The regulation of dendritic protein synthesis seems to be largely independent of the cell soma, inasmuch as isolated synaptoneurosomes respond to short pulses of a mixture of glutamate and NMDA with an increase in general protein synthesis, which is accompanied by an increase in the levels of the CaMKII protein (3). Furthermore, BDNF as well as a D1/D5 dopaminergic agonist induce the expression in dendrites of a green fluorescent protein reporter whose coding sequence is flanked by the sequences encoding the 5'- and 3'-untranslated region of CaMKII mRNA, sequences known to control CaMKII mRNA translation (4, 5).

Mammalian target of rapamycin (mTOR) plays an important role in the late phase of LTP; thus rapamycin, a specific inhibitor of TOR complex 1, prevents late phase LTP when applied during the induction phase (6). BDNF increases protein synthesis in neurons through activation of the mTOR/S6K pathway (7, 8) and potentiates LTP (9), responses that are inhibited by rapamycin (6, 10, 11). TOR complex 1 controls the component of mRNA translation necessary for cell growth, presumably through the phosphorylation of its substrates, which include eukaryotic initiation factor 4E-binding protein and the p70S6 kinase (S6K). Thus, interference or deletion of S6K results in a marked decrease in cell size during development and in response to mitogen stimulation in culture (reviewed in Ref. 12). mTOR can regulate both translational initiation and elongation, the latter by promoting the inactivation of elongation factor 2 kinase (EF2 kinase, also known as CaMKIII). EF2 kinase phosphorylates EF2 at Thr52 in the GTP-binding domain and inhibits EF2-catalyzed mRNA transit through the ribosome (13). Whereas intracellular Ca2+ activates EF2 kinase (14), activation of the mTOR/S6K as well as ERK/Rsk pathways phosphorylate and inhibit EF2 kinase, thereby promoting the elongation activity of EF2 (15).

Glutamatergic receptors are central to several activity-dependent alterations in synaptic strength that play a role in memory and learning. These receptors are also involved in the neuronal death that occurs in many chronic neurodegenerative disorders (16). The factors that promote the physiological and pathological functions of the NMDA receptors are incompletely defined, but the intensity and duration of stimulation (17) together with the synaptic versus extrasynaptic localization of the receptor (18) are suggested as factors that can direct the response to one or the other outcome. Herein we characterize the effect of glutamatergic activation on the mTOR/S6K pathway in cultured mouse neurons and demonstrate that physiologic stimulation promotes mTOR activation independently of the NMDA receptor through a calcium/calmodulin signal controlled by voltage-dependent Ca2+ channels; by contrast, excitotoxic glutamatergic stimulation inhibits mTOR signaling.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
The "Materials and Methods" are provided in the supplemental material.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
A Short Glutamatergic Stimulus Induces the Activation of the S6K Pathway, whereas a Sustained Stimulus Is Inhibitory—Mimicking the physiological glutamatergic stimulus that occurs at a synapse is not a simple task, inasmuch as neurons in culture are very sensitive to supra-physiologic concentrations of, and/or inappropriately prolonged exposure to, glutamatergic agonists. For example, NMDA at 25 µM activates, whereas 100 µM inhibits, ERK signaling (19), and continuous exposure to glutamate for periods needed to study protein synthesis regulation, i.e. 30 min or more, leads to massive cell death (20). In an effort to achieve a glutamatergic stimulation that mimics, as closely as possible, a physiologic stimulus, we employed a very short glutamatergic treatment protocol; this was accomplished by adding a mixture of glutamate (10 µM) and NMDA (50 µM) followed 5 s later by the addition of the NMDA receptor antagonist APV (120 µM). This treatment protocol is hereafter referred to as GNA.

Whereas the GNA protocol resulted in an increase in the phosphorylation of S6K, S6, Akt, and ERK in cortical neurons when analyzed 30 min after application of the stimulus, the same concentrations of glutamate and NMDA applied without the addition of APV 5 s later led to a reduction in the phosphorylation of these proteins below the initial levels (Fig. 1A). The magnitude of the increase in the phosphorylation of S6K, Akt, and ERK induced by GNA (estimated by immunoblot) is comparable but slightly less than that elicited by BDNF (Fig. 1, B and C); however, the GNA-induced increase in S6 phosphorylation is only about half that elicited by BDNF (Fig. 1C). The very brief nature of the GNA stimulus biases toward underestimation and makes a quantitative comparison to BDNF unreliable.



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 1.
Brief glutamatergic stimulation and synaptic stimulation induce activation of the S6K pathway. A, neuronal cultures were harvested 30 min after treatment with GNA (glutamate, 10 µM plus NMDA, 50 µM, followed 5 s later by APV, 120 µM) or with continuous stimulation with glutamate (10 µM) plus NMDA (50 µM)(GluNMDA). B, treatment with GNA as described for A or BDNF (50 ng/ml). Immunoblots were performed against the phosphorylated forms of S6K (pS6K), ribosomal S6 protein (pS6), Akt, and ERK. C, BDNF and GNA induce an increase in phosphorylation of S6K, ribosomal S6 protein, Akt, and ERK; p < 0.05 compared with control; the number of experiments is indicated within each bar. D, 6-day (upper) or 12-day (lower) old cultures were treated with GNA or 50 µM bicuculline, supplemented with 2.5 mM 4-AP. E, BAP-stimulated S6 and ERK phosphorylation is significantly higher in twelve day cultures, when compared with 6-day cultures; *, p < 0.05. F, 12-day cultures were pretreated for 30 min with BAP followed by the addition of glutamate (100 µM) or carrier; cultures were harvested 10 or 30 min thereafter. All blots shown except for tubulin are phosphospecific; blots of kinase polypeptides (data not shown) indicated equal loading. In A, B, D, and F, lane C = control.

 
Stimulation of Synaptic Activity in Culture Activates the S6K Pathway— Neuronal cultures contain inhibitory interneurons that control basal neuronal activity through the activation of the GABAA receptor. Therefore, the inhibition of this receptor with bicuculline, a GABAA receptor antagonist, together with 4-AP, a weak potassium channel blocker, is able to produce a selective increase in basal synaptic activity, i.e. activating receptors localized at synapses, without activating extrasynaptic receptors (18).

The elaboration of these inhibitory GABAergic interneurons requires considerable maturation of primary neuronal cultures (21). Thus whereas a vigorous response to GNA is evident in cultures stimulated 6 days after plating/attachment, the response to GNA is fully attenuated by 12 days in culture. In contrast, bicuculline (50 µM) plus 4-aminopyridine (2.5 µM) (hereafter called BAP), which elicits little or no response in 6-day cultures, produces a robust activation of p70S6 kinase and ERK when applied to neurons after twelve days in culture. These results reflect the maturation of inhibitory GABAergic interneurons and/or glutamatergic synapses (22) and indicate that synaptic stimulation is a very strong activator of signaling pathways leading to the S6K and ERK (Fig. 1, D and E).



View larger version (55K):
[in this window]
[in a new window]
  		FIGURE 2.
Activation of S6K by GNA and BAP is dependent on calcium signaling. Neuronal cultures were pretreated for 30 min with the indicated inhibitors at the concentrations described in the methods and then stimulated with BDNF (A–D) or GNA (A, C, D) or BAP (B, D) or KCl (E). Thirty min thereafter, cells were harvested, and extracts were subjected to immunoblot as indicated. In A, B, C, and E, lane C = control.

 
In contrast to BAP, which selectively disinhibits receptors localized at synapses, bath application of glutamate activates both synaptic and extrasynaptic receptors. Activation of extrasynaptic glutamatergic receptors was shown previously to block the induction of cAMP-response element-binding protein (CREB) phosphorylation by BAP (18). Herein we show that when neurons, 12 days in culture, are treated with glutamate (100 µM) after a 30-min pretreatment with BAP, the BAP-induced phosphorylation of S6 is reduced by 10 min and abolished after 30min. Thus activation of extrasynaptic glutamate receptors, in a dominant fashion, blocks the activation of the mTOR/S6K pathway induced by synaptic activation (Fig. 1F).

Glutamtergic Stimulation of the mTOR Pathway Requires Calcium Entry through L-type Voltage-dependent Calcium Channels—We sought to characterize the pathway responsible for glutamatergic activation of mTOR signaling. Activation of p70S6 kinase by receptor tyrosine kinases (e.g. BDNF/TrkB) requires the activation of Type 1 PI3K and is ultimately mediated by the sequential phosphorylation of S6 kinase by the rapamycin-sensitive TOR complex 1 (TORC1) and the kinase PDK1; thus BDNF activation of the mTOR pathway to p70S6K is inhibited by the PI3K inhibitors, Ly294002 or wortmannin, and by the TORC1 inhibitor, rapamycin (7, 8). Similarly, GNA- and BAP-stimulated phosphorylation of p70S6K and S6 is strongly inhibited by Ly294002 or wortmannin and by rapamycin (Fig. 2, A and B). The PI3K inhibitor also prevents the GNA phosphorylation of Akt (Thr473) and of the Akt substrate, GSK3{beta}(Ser9) (Fig. 2A); the latter are, however, resistant to rapamycin. Neither Ly294002 nor rapamycin has any significant effect on BAP (Fig. 2A) or GNA (data not shown) activation of ERK (Fig. 2B). Thus, as with BDNF, PI3K is necessary for GNA/BAP activation of Akt and p70S6 kinase, and the latter also requires the TORC1, whereas activation of ERK is presumably driven by Ras-GTP through a PI3K-independent mechanism.



View larger version (68K):
[in this window]
[in a new window]
  		FIGURE 3.
Regulation of EF2 phosphorylation by various stimuli. A, the effect of BAP (left) GNA (middle) or BDNF (right) on EF2 phosphorylation in neuronal cultures, directly or pretreated with calmidazolium (Calmz) or KN93. Lane C = control. B, the time course of EF2 and ERK phosphorylation in response to BDNF, synaptic stimulation (BAP), KCl depolarization, or sustained (GluNMDA) glutamatergic stimulation.

 
As regards the GNA/BAP responsive elements further upstream, APV, a potent and selective inhibitor of the ionotropic NMDA receptor, strongly suppresses BAP (Fig. 2B) and GNA (data not shown) activation of ERK. Surprisingly, however, APV does not alter GNA or BAP activation of the mTOR pathway (Fig. 2, B–D). Glutamatergic stimulation of the mTOR pathway does require Ca2+/calmodulin, inasmuch as blockade of calmodulin with calmidazolium (Fig. 2, A–C) or inhibition of CaMKII with KN93 (Fig. 2, B and C) each completely inhibits the activation of S6K and the phosphorylation of S6. BDNF-stimulated phosphorylation of S6K is also inhibited by both KN93 and by calmidozolium (Fig. 2C). Nifedipine, an inhibitor of L-type voltage-dependent calcium channels (L-VDCC), strongly inhibits both S6 and ERK phosphorylation induced by GNA or BAP (Fig. 2, B and D) but not by BDNF (Fig. 2D), which can mobilize intracellular calcium stores by activation of phospholipase C. Direct activation of voltage-dependent Ca2+ channels, achieved by depolarization of neurons with KCl (60 mM for 30 min), induces a strong increase in the phosphorylation of S6, in a mechanism blocked by calmidazolium, the L-type voltage-dependent Ca2+ channel blockers nifedipine and nimodipine as well as by KN93 (Fig. 2E). These results indicate that the GNA and BAP glutamatergic stimulation protocols promote activation of the mTOR/S6K pathway by an NMDA receptor-independent activation of L-VDCC; in contrast, BDNF signaling to CaMKII is completely independent of both NMDA receptor as well as L-VDCC.

Elongation Factor 2 Phosphorylation Is Inhibited by Depolarization or Synaptic Stimulation but Increased by Extrasynaptic Glutamatergic Stimulation—EF2 facilitates peptide chain elongation and can be negatively regulated by EF2 kinase (EF2K). The latter is activated by Ca2+/calmodulin and inhibited by both the ERK and the mTOR pathways, through direct phosphorylation of EF2K in its calmodulin-binding domain by either Rsk or p70S6 kinase, respectively. Treatment of neurons with calmidazolium completely abolishes phosphorylation of EF2 (Fig. 3A), presumably by direct inhibition of EF2K, whereas the relatively selective CaMKII inhibitor KN93 increases the phosphorylation of EF2 in the presence of GNA and BDNF (Fig. 3A), presumably reflecting the ability of KN93 to abolish activation of ERK and mTOR signaling (Fig. 2, B, C, and E); inhibition of mTOR with rapamycin also increases the phosphorylation of EF2 (data not shown).

Neurotropic and physiological glutamatergic stimulation leads to the increase in intracellular Ca2+ but also results in an increase in protein synthesis; this suggests that the activation of ERK and S6K accompanying such stimuli is dominant in the regulation of EF2. Consistent with this view, BDNF gives a very robust activation of ERK paralleled by a profound inhibition of EF2 phosphorylation (Fig. 3B). BAP- and KCl-induced depolarization each cause a progressive decrease in the phosphorylation of EF2, which, compared with BDNF, is relatively slow in onset, perhaps due to the less robust activation of ERK. In contrast to BAP and KCl, the continuous presence of glutamate plus NMDA without the addition of APV (GluNMDA), which suppresses ERK and mTOR signaling, results in a progressive increase in EF2 phosphorylation (Fig. 3B). Thus, despite the ability of all these stimuli to incease intracellular Ca2+, the Ca2+-dependent phosphorylation of EF2 is inhibited if there is concomitant activation of ERK/Rsk and/or mTOR/p70S6 kinase.

Catecholamines Enhance GNA-stimulated S6 Phosphorylation—Activation of D1/D5 dopaminergic receptors was recently shown to increase protein synthesis in dendrites of hippocampal neurons (5). Dopaminergic and NMDA receptors interact directly and dopaminergic receptor activation protects neurons from NMDA-induced excitotoxicity; this protection is prevented by a PI3K inhibitor (23). To assess whether there is an interaction between the glutamatergic and dopaminergic activated pathways in the regulation of the mTOR/S6K pathway, neurons were treated with dopamine, resulting in a small, statistically insignificant increase in the phosphorylation of S6. In contrast to the borderline stimulation by dopamine alone, the concomitant presence of dopamine and GNA produces a further increase in the phosphorylation of S6 when compared with that elicited by GNA alone (Fig. 4, A and B). An augmentation of GNA-stimulated S6 phosphorylation is even more clear-cut with another catecholamine, norepinephrine (NE) (Fig. 4, A and B), which significantly stimulates S6 phosphorylation by itself and when present with GNA promotes a further increase in S6 phosphorylation that is significantly greater than that elicited by GNA alone. The response of ERK to dopamine and NE alone is similar to that seen with S6 phosphorylation; however, ERK activation in response to GNA is not further increased by the presence of NE or dopamine (Fig. 4C).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The mTOR/S6K pathway controls the component of protein synthesis that is particularly important for cell growth as well as for neuronal plasticity, inasmuch as the late phase of LTP is inhibited comparably by inhibitors of overall protein synthesis and by rapamycin. Because the glutamatergic system is a fundamental player in synaptic plasticity, we investigated the regulation of the mTOR/S6K pathway using stimulation protocols designed to mimic the plasticity-inducing stimulation that occurs in the intact brain.

Previous studies using hippocampal slices (24) showed that ERK is activated by LTP-inducing stimulation, whereas excessive NMDA receptor stimulation inactivates this kinase (19). Similarly, we find that short and long exposures to glutamatergic stimulation produce, respectively, stimulatory and inhibitory effects on S6K, S6, Akt, and ERK phosphorylation, reinforcing the importance of a short pulse of glutamatergic stimulation for the activation of these pathways. Thus, despite the short duration between agonist and antagonist addition, GNA appears to provide a bona fide physiologic glutamatergic stimulation. The slow development in culture of inhibitory postsynaptic GABAergic interneurons enables the selective stimulation of endogenous synapses, through inhibition of GABAA receptor; such a maneuver (i.e. BAP) also activates the S6K and ERK pathways (Fig. 1D). As with GNA, sustained and generalized glutamatergic stimulation generates a dominant inhibition over BAP stimulation. A third illustration of this difference between physiologic and excitotoxic stimulation is seen in the phosphorylation of EF2; as shown previously (14), supraphysiologic glutamatergic stimulation, which suppresses ERK and S6K activity, increases EF2 phosphorylation. In contrast, physiologic glutamatergic stimulation by BAP and GNA results in a decrease in phosphorylation of EF2. Thus although all require a Ca2+ signal, the mTOR/S6K and/or ERK/Rsk pathways are dominant to the EF2K pathway.

The dependence of glutamatergic S6K activation on PI3k and the rapamycin-sensitive TORC1, as seen with BDNF stimulation of neurons (7), is not surprising. More unexpected is the finding that activation of the S6K pathway by GNA and BAP is strongly inhibited by L-VDCC blockers but is unaffected by the NMDA receptor antagonist APV (Fig. 2, B–D) or by the PLC inhibitor U73122 [GenBank] (data not shown). Thus the L-VDCC are indispensable for activation of the mTOR/S6K pathway in neurons by glutamatergic stimulation, by endogenous synaptic stimulation as well as by KCl-induced depolarization. Glutamatergic or synaptic stimulation can cause depolarization through activation of AMPA receptors and thereby activate the L-VDCC (25). Synaptic NMDA receptors, although critical for BAP-induced ERK activation, do not participate in BAP activation of the mTOR/S6K pathway. These results illustrate that Ca2+ entry through postsynaptic NMDA receptors and L-type VDCC contributes to different postsynaptic pools of Ca2+, in that the signal transduction pathways engaged by these two Ca2+ entry pathways differ, at least in part. Although both components are engaged during most protocols productive of LTP, earlier work has indicated that the two pathways can be recruited differentially by different patterns of electrical stimulation (26). Moreover, the selective activation of Ca2+ entry by one or the other of these two pathways can each generate LTP responses in vitro that are distinct in their sensitivity to various protein kinase inhibitors (27), and when engaged selectively in vivo, these two pathways have distinguishable effects in a test of spatial memory, with inhibition of L-VDCC impairing the retention but not the acquisition of a learned task (28).



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 4.
Dopamine or norepinephrine enhance selectively the glutamatergic stimulation of S6 phosphorylation. A, cortical neuronal cultures were incubated with GNA, NE, or dopamine (DOPA) singly or in the combinations shown and harvested 30 min later. A representative immunoblot of phospho-S6 and pERK is shown. Lane C = control. B, the densitometric intensity of the pS6 band in extracts from stimulated cells was divided by the intensity of the pS6 band in unstimulated cells and expressed as fold stimulation. The number of independent experiments is indicated in each bar. The effect of dopamine is not significant (p = 0.13), whereas the response to GNA (p = 0.03), GNA + dopa (p = 0.01), NE (p = 0.04) and GNA+NE (p = 0.01) is significant; the p value of the comparison between GNA alone and GNA + dopamine (0.07) or GNA + NE (0.02) is indicated in the latter bars. C, as described for B, for the fold stimulation of pERK.

 
Catecholaminergic neurons are concentrated in specific brain areas, such as substantia nigra in the case of dopaminergic neurons and locus coeruleus for norepinephrine neurons. Axons sprouting from these structures irrigate virtually all brain areas modulating the activity in these regions (29). It is believed that catecholamines are key regulators of mood and thus are responsible for the emotional background of memories (30). The ability of concomitant glutamatergic and catecholaminergic stimulation to enhance glutamatergic S6 phosphorylation is consistent with a variety of previous reports describing mutual reinforcement between these two synaptic inputs. Dopamine and NE affect synaptic potentiation, with dopamine alone or agonists of D1/D5 dopamine receptors inducing a slow, protein synthesis-dependent, synaptic potentiation in hippocampal slice that requires glutamatergic activation of NMDA receptors (31). Norepinephrine is also known to modulate LTP, restoring the LTP-inducing potency of high frequency stimulation in older animals (32). Activation of D1/D5 receptors lead to an increase in protein synthesis, in an mTOR-dependent way. Moreover, NMDA receptor activity is required for the dopamine agonist-induced increase in surface GluR and miniature excitatory postsynaptic currents (5), indicating the importance of the signaling of the glutamatergic and dopaminergic receptors toward protein synthesis. Thus, the additive effect of GNA with dopamine/norepinephrine on activation of the mTOR/S6K pathway suggests that this phenomenon may account in part for the synergistic regulation of protein-synthesis dependent synaptic plasticity.

In conclusion, glutamatergic or synaptic stimulations designed to mimic physiological stimuli increase the activation of S6K and the phosphorylation of S6 in a VDCC-, Ca2+-calmodulin-, CaMKII-, and PI3K-dependent mechanism, and this increase is further augmented by co-stimulation with catecholamines. In contrast, excitotoxic glutamatergic stimulation dominantly inhibits the mTOR/S6K pathway.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Awards DK17776 and CA73818 (to J. A.) and by the Conselho Nacional de Desenvolvimento Cientifico e Tecnológico and Universidade Federal do Rio Grande do Sul (to G. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{boxs} The on-line version of this article (available at http://www.jbc.org) contains the Materials and Methods and supplemental Discussion and Refs. S1–S8. Back

1 To whom correspondence should be addressed: Dept. of Molecular Biology, Richard B. Simches Research Bldg., 6th Floor, 185 Cambridge St.-CPZN-7402, Boston, MA 02114. Tel.: 617-726-6909; Fax: 617-726-5649; E-mail: avruch{at}molbio.mgh.harvard.edu.

2 The abbreviations used are: LTP, long term potentiation; APV, 2-amino-5-phosphonovaleric acid; NMDA, N'-methyl-D-aspartate; GNA, glutamate + NMDA + APV; 4-AP, 4-aminopyridine; BAP, bicuculine + 4-AP; VDCC, voltage-dependent calcium channel(s); GSK3, glycogen synthase kinase 3; mTOR, mammalian target of rapamycin; TORC1, rapamycin-sensitive TOR complex 1; S6K, p70S6 kinase; ERK, extracellular regulated protein kinase; PI3K, phosphatidylinositol 3-OH-kinase; CaMKII, calcium/calmodulin-dependent protein kinase 2; EF2, elongation factor 2; EF2K, EF2 kinase; GABA, {gamma}-aminobutyric acid; BDNF, brain-derived neurotrophic factor; NE, norepinephrine. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Lisman, J., Schulman, H., and Cline, H. (2002)Nat. Rev. Neurosci. 3, 175–190[CrossRef][Medline] [Order article via Infotrieve]
  2. Bhalla, U. S., and Iyengar, R. (1999) Science 283, 381–387[Abstract/Free Full Text]
  3. Scheetz, A. J., Nairn, A. C., and Constantine-Paton, M. (2000) Nat. Neurosci. 3, 211–216[CrossRef][Medline] [Order article via Infotrieve]
  4. Aakalu, G., Smith, W. B., Nguyen, N., Jiang, C., and Schuman, E. M. (2001) Neuron 30, 489–502[CrossRef][Medline] [Order article via Infotrieve]
  5. Smith, W. B., Starck, S. R., Roberts, R. W., and Schuman, E. M. (2005) Neuron 45, 765–779[CrossRef][Medline] [Order article via Infotrieve]
  6. Cammallieri, M., Lutjens, R., Berton, F., King, A. R., Simpson, C., Francesconi, W., and Sanna, P. P. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 14368–14373[Abstract/Free Full Text]
  7. Takei, N., Kawamura, M., Hara, K., Yonezawa, K., and Nawa, H. (2001) J. Biol. Chem. 276, 42818–42825[Abstract/Free Full Text]
  8. Takei, N., Inamura, N., Kawamura, M., Namba, H., Hara, K., Yonezawa, K., and Nawa, H. (2004) J. Neurosci. 24, 9760–9769[Abstract/Free Full Text]
  9. Lynch, M. A. (2003) Physiol. Rev. 84, 87–136
  10. Tang, S. J., Reis, G., Kang, H., Gingras, A. C., Sonenberg, N., and Schuman, E. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 467–472[Abstract/Free Full Text]
  11. Sanna, P. P., Cammalleri, M., Berton, F., Simpson, C., Lutjens, R., Bloom, F. E., and Francesconi, W. (2002) J. Neurosc. 22, 3359–3365[Abstract/Free Full Text]
  12. Hay, N. A., and Sonenberg, N. (2004) Genes Dev. 18, 1926–1945[Abstract/Free Full Text]
  13. Browne, G. J., and Proud, C. G. (2002) Eur. J. Biochem. 269, 5360–5368[Medline] [Order article via Infotrieve]
  14. Marin, P., Nastiuk, K. L., Daniel, N., Girault, J. A., Czernik, A. J., Glowinski, J., Nairn, A. C., and Premont, J. (1997) J. Neurosc. 17, 3445–3454[Abstract/Free Full Text]
  15. Wang, X., Li, W., Williams, M., Terada, N., Alessi, D. R., and Proud, C. G. (2001) EMBO J. 20, 4370–4379[CrossRef][Medline] [Order article via Infotrieve]
  16. Hardingham, G. E., and Bading, H. (2003) Trends Neurosci. 26, 81–89[CrossRef][Medline] [Order article via Infotrieve]
  17. Sutton, G., and Chandler, L. J. (2002) J. Neurochem. 82, 1097–1105[CrossRef][Medline] [Order article via Infotrieve]
  18. Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002) Nat. Neurosc. 5, 405–414[Medline] [Order article via Infotrieve]
  19. Chandler, L. J., Sutton, G., Dorairaj, N., and Norwood, D. (2001) J. Biol. Chem. 276, 2627–2636[Abstract/Free Full Text]
  20. McDonald, J. W., Silverstein, F. S., and Johnston, M. V. (1988) Brain Res. 459, 200–203[CrossRef][Medline] [Order article via Infotrieve]
  21. Kato-Negishi, M., Muramoto K, Kawahara, M., Kuroda, Y., and Ichikawa, M., (2004) Brain Res. 152, 99–108
  22. Lesuisse, C., and Martin, L. J. (2002) J. Neurobiol. 51, 9–23[CrossRef][Medline] [Order article via Infotrieve]
  23. Lee, F. J. S., Xue, S., Pei, L., Vukusic,B., Chery, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X., and Liu, F., (2002) Cell 111, 219–230[CrossRef][Medline] [Order article via Infotrieve]
  24. English, J. D., and Sweatt, J. D. (1996) J. Biol. Chem. 271, 24329–24332[Abstract/Free Full Text]
  25. Malinow, R., and Malenka, R. C., (2002) Annu. Rev. Neurosci. 25, 103–126[CrossRef][Medline] [Order article via Infotrieve]
  26. Morgan, S. L., Coussens, C. M., and Teyler, T. J. (2001) Neurobiol. Learn. Mem. 76, 229–238[CrossRef][Medline] [Order article via Infotrieve]
  27. Cavus, I., and Teyler, T. (1996) J. Neurophysiol. 76, 3038–3047[Abstract/Free Full Text]
  28. Woodside, B. L., Borroni, A. M., Hammonds, M. D., and Teyler, T. J. (2004), Neurobiol. Learn. Mem. 81, 105–114[CrossRef][Medline] [Order article via Infotrieve]
  29. Goridis, C., and Rohrer, H. (2002) Nat. Neurosci. 3, 531–541
  30. McGaugh, J. L. (2002) Trends Neurosci. 25, 456–461[CrossRef][Medline] [Order article via Infotrieve]
  31. Huang, Y. Y., and Kandel, E. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2446–2450[Abstract/Free Full Text]
  32. Izumi, Y., and Zorumski, C. R. (1999) Synapse 31, 196–202[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cereb CortexHome page
H. Schicknick, B. H. Schott, E. Budinger, K.-H. Smalla, A. Riedel, C. I. Seidenbecher, H. Scheich, E. D. Gundelfinger, and W. Tischmeyer
Dopaminergic Modulation of Auditory Cortex-Dependent Memory Consolidation through mTOR
Cereb Cortex, March 6, 2008; (2008) bhn026v2.
[Abstract] [Full Text] [PDF]

Home page
 Learn. Mem.Home page
M. D. Antion, M. Merhav, C. A. Hoeffer, G. Reis, S. C. Kozma, G. Thomas, E. M. Schuman, K. Rosenblum, and E. Klann
Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity
Learn. Mem., January 3, 2008; 15(1): 29 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Q. Hong-Brown, C. R. Brown, D. S. Huber, and C. H. Lang
Alcohol Regulates Eukaryotic Elongation Factor 2 Phosphorylation via an AMP-activated Protein Kinase-dependent Mechanism in C2C12 Skeletal Myocytes
J. Biol. Chem., February 9, 2007; 282(6): 3702 - 3712.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Huang, B. N. Kang, J. Tian, Y. Liu, H. R. Luo, L. Hester, and S. H. Snyder
The Cationic Amino Acid Transporters CAT1 and CAT3 Mediate NMDA Receptor Activation-Dependent Changes in Elaboration of Neuronal Processes via the Mammalian Target of Rapamycin mTOR Pathway
J. Neurosci., January 17, 2007; 27(3): 449 - 458.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Gong, C. S. Park, N. R. Abbassi, and S.-J. Tang
Roles of Glutamate Receptors and the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Activity-dependent Dendritic Protein Synthesis in Hippocampal Neurons
J. Biol. Chem., July 7, 2006; 281(27): 18802 - 18815.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/46/38121    most recent
C500363200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenz, G.
Right arrow Articles by Avruch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenz, G.
Right arrow Articles by Avruch, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.